PErsonalized TReatment for Endometrial Carcinoma (PETREC)
Endometrial Adenocarcinoma
About this trial
This is an interventional treatment trial for Endometrial Adenocarcinoma focused on measuring Endometrial carcinoma, Molecular classification, Adjuvant therapy
Eligibility Criteria
Inclusion Criteria: Age 18 to 100 years WHO performance status 0 to 2 Stage I-II molecular integrated high-intermediate or high-risk endometrial carcinoma Exclusion Criteria: Age <18 years or >100 years WHO performance status >2 Uterine sarcoma A history of malignancy within 5 years Previous pelvic radiotherapy An interval of >30 days between surgery and start of chemotherapy or >8 weeks between surgery and start of radiotherapy (longer intervals may be permitted with investigator´s approval)
Sites / Locations
- Helsinki University HospitalRecruiting
Arms of the Study
Arm 1
Arm 2
Arm 3
Experimental
Experimental
Experimental
p53 abn subtype and nonendometrioid carcinomas
MMR-D molecular subgroup
NSMP molecular subgroup
p53 abn stage I-II MI (myometrial invasion) >0%; MMR-D/NSMP nonendometrioid stage I-II MI >0%
MMR-D stage IA-B grade 1-2, substantial LVSI; MMR-D stage IA grade 3, substantial LVSI; MMR-D stage IB grade 3; MMR-D stage II grade 1-3;
NSMP stage IA-B grade 1-2, substantial LVSI; NSMP stage IA grade 3, substantial LVSI; NSMP stage IB grade 3; NSMP stage II grade 1-3;